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Abstract 
Many people, particularly in developing countries, die from curable or manageable diseases without 
access to medicine.  After the TRIPS Agreement was brought into force, access to medicine in developing 
countries became worse and even deteriorated development.  To solve the controversy in interpreting the 
TRIPS Agreement and the resulting public health crises, the Doha Declaration was adopted, recognizing the 
flexibilities of the TRIPS Agreement as effective and vital manners to promote access to medicines.  However, 
there are still many difficulties encountered by developing countries in full implementation of the Doha 
Declaration.  Therefore, this paper aims to reexamine and reaffirm access to medicine as an international 
human right, claiming it should be accommodated under the WTO framework, and also proposes several 
possible solutions to advance the accessibility of medicine.   
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I.  Introduction 
The public health crises mainly confronted by developing countries are involved multi-dimensional of 
problems, particularly with regard to the conflict between access to medicine and the pharmaceutical patent 
regime.  Following the Agreement on Trade-related Intellectual Property Rights (the TRIP Agreement), which 
links trade and the intellectual property rights, the problem of access to medicine in developing countries has 
worsened and become more complex and worse.  When developing countries try to struggle and fight for its 
public health needs under the World Trade Organization (the WTO) framework,  they are met with the 
pressure and obstacles set by the developed world and its pharmaceutical industry that assert patent protection 
serves as an incentive for invention.  Developing and developed countries perceive the TRIPS Agreement in 
different ways, thereby causing conflicts among nations and preventing appropriate measures from reaching 
public health emergencies.  Therefore, it is beneficial to delve into this study by exploring the interrelationships 
among the underlying value of pharmaceutical patent, access to medicines, and the advancement of public 
health;  thus providing grounds to figure out a way to balance the interpretation of the TRIPS Agreement and 
other documents under the WTO framework, in particular, to ensure access to medicine without sacrificing 
incentives to innovation.  Furthermore, the case that the Taiwanese government approved the compulsory 
license of Tamiflu in 2005, which was the first compulsory license of Tamiflu granted in the world, when the 
possibility of an Avian Influenza pandemic, also inspired me to engage in this study to explore the conflict 
between pharmaceutical patent rights and public health needs.   4 
Part II of this paper gives an overview of how the public health needs are impacted by access to 
medicine.  First, I review the global health crises in the 21
st century, pointing out the importance of access to 
medicine, and then indicate that the high cost of drugs price is a major barrier for developing countries to 
access medicine.  In Part III, I probe into the interrelationship between pharmaceutical patent protection and 
access to medicine.  Beginning with a review of the history of patent law development, particularly with an 
emphasis on the patentability of pharmaceutical products, this paper suggests that patents are granted at the 
discretion of the national authorities as a mechanism to promote development of country.  Then I review the 
international patent law before and after the TRIP Agreement was introduced, examining the flexibilities – in 
particular the parallel imports and compulsory licensing under the TRIPS Agreement – used to accommodate 
the public health needs to access to medicine.  Part IV of this paper observes the difficulties experienced by 
developing countries in adopting the TRIPS flexibilities on pharmaceutical patents, the efforts made in the 
Doha Declaration attempting to resolve these difficulties, and also gives an evaluation of the Doha Declaration.  
In Part V, I first locate the right of access to medicine under the international human right framework, and 
secondly claim that, under such framework, the human right of access to medicine surpasses pharmaceutical 
patent holder’s right in public health emergencies.  Third, I propose possible solutions to the global public 
health concerns of access to medicine. 
By investigating the public health crises mainly faced by developing countries, we can observe the 
intense conflicts between different rights and obligations.  While the topics mentioned in this paper have long   5 
been debated among developing and developed countries, this paper intends to deliberate the issue from a 
more fundamental perspective, and tries to propose possible solutions while serving as a preliminary research 
in this regard for future study.  
 
II.  How Does the Access to Medicine Influence Public Health Needs? 
1.  Global Public Health Threats in the 21
st Century 
In addition to the spread of food borne illnesses and environmental disasters, epidemic-prone diseases 
pose a major threat to people’s health in the 21
st century.
1  AIDS, malaria, and tuberculosis have been widely 
known to cause high mortality rates
2 in the developing and least developed countries in Africa, South America 
and Asia before this century.  Some newly emerging diseases in the 21
st century, such as Severe Acute 
Respiratory Syndrome (SARS)
3 and avian influenza in humans, even fuel the global concern for the battle 
against infectious diseases.  With the mobility and interdependence of countries in today’s world, the speed in 
which diseases spread is faster than ever before.
4  
Take the AIDS prevalence as an example
5 for illustrating an epidemic’s impact on the socio-economic 
                                                 
1 World Health Organization, The World Health Report 2007: A safer future: global public health security in the 21st century. Geneva: 
World Health Organization (2007), http://www.who.int/whr/2007/en/index.html 
2 Infectious diseases claim more than 10 million people’s life each year, and among them, more than 90 percent of death happens in the 
developing world. See Ellen’t Hoen, TRIPS, Pharmaceutical Patents, and Access to Essential Medicines: A Long Way from Seattle to 
Doha, 3 Chi. J. Int'l L. 27, 1 (2002). 
3 When SARS swept away East Asia in 2003, I was in Taiwan and witnessed the SARS panic. This experience also aroused my interest 
in conducting this study in the area of public health law.    
4 “Since the 1970s, newly emerging diseases have been identified at the unprecedented rate one or more per year. There are now nearly 
40 diseases that were unknown a generation ago. In addition, during the last five years, WHO has verified more than 1100 epidemic 
events worldwide.” Supra note 1, at x.  
5 On account of the HIV/AIDS pandemic, it is currently the most representative example stating the conflict between citizens/patients   6 
aspects of a society: in 2007, there are around 33.2 million people worldwide, including 2.5 million children, 
infected  with  AIDS,  and  2.1  million  of  whom,  including  330,000  children,  died  of  this  epidemic.  
Geographically, sub-Saharan Africa has just over 10 percent of the world’s population
6, but it has always been 
the most infected area.  22.5 million people, which is 68% of all HIV positive patients, living with AIDS are in 
this region, making up over three-fourth of all AIDS deaths in 2007.
7  The HIV/AIDS threat has impeded 
regional economic growth and ruined  human capital because many HIV positive patients are young adults 
who are in the productive age for their households.  Thus their infectious status leads to huge demands of 
medical treatment, while their premature mortality leads to a small number of the labor force and leaves the 
expected pay-off burden to their children as the mechanism to transmit knowledge and abilities from one 
generation to another is strongly weakened through the loss of income, expense on healthcare and burial of the 
parents.
8  Besides its impact on family, nationally, the decreasing output and increasing expenditure on 
healthcare are obstacles for the government to manage its resources, let alone to get rid of its poor plight or to 
shorten the difference among countries and regions.  The AIDS pandemic has become a development crisis, 
rather than just a public health issue.  If the response to the epidemic is delayed, future generations have to 
                                                                                                                                                            
and access to medicine. It is not the only one case for sure. See HOLGER HESTERMEYER, HUMAN RIGHTS AND THE WTO: THE CASE OF 
PATENTS AND ACCESS TO MEDICINES 15 (2007).   
6 World Bank, HIV/AIDS in Africa – ACTafrica, 
http://web.worldbank.org/WBSITE/EXTERNAL/COUNTRIES/AFRICAEXT/EXTAFRHEANUTPOP/EXTAFRREGTOPHIVAI
DS/0,,contentMDK:20411613~menuPK:717155~pagePK:34004173~piPK:34003707~theSitePK:717148,00.html, (last visited March 
24, 2008). 
7 UNAIDS, WHO, 2007 AIDS Epidemic Update (2007), 
http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2007/ 
8 Clive Bell, Shantayanan Devarajan, Hans Gersbach, "The long-run economic costs of AIDS: theory and an application to South 
Africa", World Bank Policy Research Working Paper No. 3152 (2003), 
http://www1.worldbank.org/hiv_aids/docs/BeDeGe_BP_total2.pdf.. See also Robert Greener, AIDS and macroeconomic impact, in S, 
Forsyth (ed.): State of The Art: AIDS and Economics. IAEN, 49–55 (2002).   7 
suffer from an even worse collapse.
9  
Not only do  people living in the developing and least developed countries are suffered from the 
infectious  diseases that  deteriorate even  their  poverty  and  living  environment,  but  some  people  in  the 
developed countries are now under epidemic health risks.  Anthrax attacks to the United States in 2001 
emphasized the importance of coping with countermeasures to the issue.  Developed countries can no longer 
stand aside and put themselves out of stormy epidemics.  
 
2.  The Right to Access Medicines 
Access to medicine plays a critical role in improving public health because modern medical science 
heavily relies on medicine or vaccination to cure or to prevent diseases.  There are effective medical treatments 
for  most  of  the  leading  infectious  diseases,  including  acute  respiratory  infections,  HIV/AIDS,  malaria, 
tuberculosis and the complications of measles.
10 But most of time, people in the developing world lacking 
health care infrastructure die for having no access to medicines.   
However, not every kind of medicine can be legitimately claimed as a  right to access medicine.  
According to the social value of medicine, it can be divided into three categories – essential medicine, new 
medicine, and medicine that does not yet exist.  The WHO defines essential drugs as “those that satisfy the 
                                                 
9 UNAIDS, Supra note 7.  
10 WHO, WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy - 2000-2003, Geneva: WHO, 
http://www.who.int/medicinedocs/en/d/Jwhozip16e.4#Jwhozip16e.4 (last visited March 24, 2008).   8 
priority health care needs of the population,” and most of them are off-patent.
11  Access to essential medicine is 
particularly important in the issue and can be claimed as a right because it means that such effective and safe 
drugs are greatly related to public health.  Furthermore, essential medicine can be obtained with affordable 
prices, sustainable financing, and reliable health and supply systems since it is easier for medical personnel to 
predict its side effects and interactions with other drugs, to ensure its quality.  Therefore, it is significant for 
national drug policy to afford essential medicine
12 to the needy, especially the diseases related to poverty, and 
to ensure quality, safety, and efficacy.
13  It is estimated, however, that one-third of the population lack access to 
essential drugs, over one-half of whom are in the most impoverished area in Africa and Asia.
14  Thus, the 
World Health Organization (WHO) set up a list of essential medicines
15 in 1977, as one of WHO’s primary 
health care strategies and updates the list every two years by an expert committee in an effort to provide a 
model for countries to adapt to their needs, which is especially valuable for countries with scarce resources to 
access the best medicine within available resources.
16  
 
                                                 
11 ALYNA C. SMITH, INTELLECTUAL PROPERTY RIGHTS AND THE RIGHT TO HEALTH: CONSIDERING THE CASE OF ACCESS TO MEDICINES, 
ETHICS AND LAW OF INTELLECTUAL PROPERTY: CURRENT PROBLEMS IN POLITICS, SCIENCE AND TECHNOLOGY 53 (Christian Lenk, 
Nils Hoppe, Roberto Andorno eds., 2007) 
12 The definition of essential drugs:¨Essential drugs are those that satisfy the health care needs of the majority of the population; they 
should therefore be available at all times, in adequate amounts and in the appropriate dosage forms.”, The Use of Essential Drugs, 6th 
Report of the Expert Committee, WHO Technical Report Series 850. In April 15-19, 2002, in WHO’s 12
th Expert Committee on the 
Selection and Use of Essential Medicines Meeting, the name “essential drugs” is changed into “essential medicines”, WHO, 12
th Expert 
Committee on the Selection and Use of Essential Medicines Meeting, 2002, 
http://mednet3.who.int/EMl/expcom/expcom12/expertrecommend.htm (last visited March 25, 2008).    
13 WHO, Progress in essential drugs and medicines policy, 1998-1999, WHO, Geneva, 
http://www.who.int/medicinedocs/en/d/Jh2950e (last visited March 24, 2008).  
14 WHO, WHO Medicine Strategy: 2000-2003, Geneva: WHO, http://www.who.int/medicinedocs/fr/d/Jwhozip16e.5.2 
15 WHO, WHO Model Lists of Essential Medicines, http://www.who.int/medicines/publications/essentialmedicines/en/ (last visited 
March 25, 2008) 
16 WHO, supra note 11   9 
3.  Drug Price as a Key Barrier to Access to Medicine for Developing Countries 
 “The poor cannot afford expensive medicines. Keeping an AIDS patient alive for a year can cost up to $15,000 — 24 
times the average annual income in Zimbabwe, where one in four adults is HIV-positive.”  
- Mike Moore, Former WTO Director-General 
There are two kinds of difficulties faced by developing countries in the outbreak of public health crisis – 
one is the difficulty of access to medicine; the other the difficulty of developing new drugs while the existing 
drugs are not effective enough.
17  
In the first difficulty, it is known that the worldwide distribution of epidemics is not equal.  It tends to be 
centralized in the developing or least developed areas yet the same region are also the most lack in drug access 
also congregated in the same region.  Though there are many factors relevant for patients to have access to the 
medicine needed, including the rational choice and use of drugs, continuously abundant funds, reliable drug 
supply systems etc.  Here we only discuss the factors related to the TRIPS Agreement that hinders the access 
to medicine to developing countries, that is, the high price of drugs and the low income of the people.
18  
First,  the  high  price  of  medicine  is  due  to  the  specialty  of  the  pharmaceutical  industry.    The 
pharmaceutical industry has complex industrial structure and highly professional division of labor.  It requires 
not only long research and developing periods but also a great deal of capital.  The risk and rate of return are 
                                                 
17 YA-WEN LEI,  KAIFA ZHONG GUOJIA ZAI YU MAOYI YOUGUAN ZHI ZHIHUICAICHANQUAN XIEDING XIA YAOPIN QUDE
KUNNAN ZHI YANJIU: XUNQIU KEYI JIANGU HUIYUAN GONGGONGJIANKANG ZHENGCE DE GUOJI ZHIHUICAICHANQUAN
TIZHI [Dilemma of Access to Medicines Faced by Developing Countries under the TRIPS Agreement - seeking an international 
intellectual property regime beneficial for the public health policy of members] 25, (unpublished M.A. thesis, National Chiao Tung 
University, 2004).   
18 Id.    10 
both very high.  Furthermore, given that drugs directly affect human’s safety and health, there is a strict 
premarket review of new drugs by the government.  For instance, in the United States, it takes about 10 to 15 
years for a new drug to develop from the initial chemical analysis stage through the obtainment of FDA’s 
approval as a new drug.
19  Therefore, drug price reflects its development cost in both time and money.  In low 
income economies,
20 the expenditure of high price drugs accounts for a large percentage of family burdens 
and is never affordable.  People usually have no choice but to give up medical treatment.  Moreover, when the 
spokespersons of the pharmaceutical industry or some research centers refer the high cost of drugs to their 
research and development cost in order to justify high drug prices and strong drug patents, readers should be 
careful  about  how  the  figures  are  computed,  including  the  inherent  drawbacks  of  studies,
21 and  the 
representative of “the average development cost of drugs
22”. 
 
III.  The Relationship Between Pharmaceutical Patents and Access to Medicine 
When confronting the public health crisis and difficulty in access to medicine, in the developing world, 
many non-government organizations and human rights advocates assert that pharmaceutical patents is the 
                                                 
19 PETER BARTON HUTT ET AL., FOOD AND DRUG LAW 577 (2007) 
20 The main criterion for World Bank’s country classification of economies is gross national income (GNI). According to the 2006, low 
income economies are referred to those GNI per capita $905 or less. The World Bank, Country Classification,  
http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,,contentMDK:20420458~menuPK:64133156~pagePK:641
33150~piPK:64133175~theSitePK:239419,00.html (last visited March 25, 2008) 
21 See MERRILL GOOZNER, THE $800 MILLION PILL. THE TRUTH BEHIND THE COST OF NEW DRUGS (2004). See also PUBLIC CITIZEN, 
AMERICA’S OTHER DRUG PROBLEM: A BRIEFING BOOK ON THE RX DRUG DEBATE (2002).  
22 Many drugs are funded by public funding in the process of basic research and clinical testing. See J.A. DiMasi et al., Cost of 
Innovation in the Pharmaceutical Industry, Journal of Health Economics 10, 107-142 (1991); See also SIGRID STERCKX, LACK OF 
ACCESS TO ESSENTIAL DRUGS: A STORY OF CONTINUING GLOBAL FAILURE, WITH PARTICULAR ATTENTION TO THE ROLE OF PATENTS, 
ETHICS AND LAW OF INTELLECTUAL PROPERTY: CURRENT PROBLEMS IN POLITICS, SCIENCE AND TECHNOLOGY 184-185 (Christian 
Lenk, Nils Hoppe, Roberto Andorno eds., 2007).   11 
major cause of the high prices of drugs and are therefore, the obstacles to access tp medicine.  Nevertheless, 
some developed countries and pharmaceutical companies oppose this connection, arguing that granting drug 
patents does not lead to price increasing.
23  In this section, it is necessary to first understand the purpose and 
nature of patent law and its position under World Trade Organization (hereinafter: WTO) in order to probe into 
the correlation of patents on pharmaceuticals under the TRIPS Agreement and accessibility of drugs in 
developing countries.
24  
 
1.  Overview of the Patent Law 
A. Patent Law history 
This survey of the history of patent law is intended to demonstrate that for a long time, patents have 
been granted at the discretion of the national authorities as a mechanism to advance national development, not 
as a natural law property right of inventor.  Furthermore, the legislators have tried to balance encouraging 
creativity with reducing drawbacks, such as higher prices.
25  
Early in the ancient Greece, inventions were encouraged to be brought into the society and inventors 
                                                 
23 Rozek RP, Berkowitz R., The Effects of Patent Protection on the Prices of Pharmaceutical Products, White Plains, NY: National 
Economic Research Associates (1998). Another study criticizes that this study does not new innovative drugs’ prices. Since the 
pharmaceutical company feels certain with the drug patent protection, it has advantages in bargain prices with the public health authority. 
Additionally, with the liberalization of international drug trade, pharmaceutical companies are less likely to cut down drug’ prices to less 
developed countries for fear of parallel imports. Consequently, it poses risks to access to medicine. See Bernard Pécoul et al, Access to 
Essential Drugs in Poor Countries: A Lost Battle?, Journal of the American Medical Association, Vol 281, No. 4, 366 (1999). 
24 Lei, Supra note 17, at 36 
25 Hestermeyer, supra note 5, at 18.    12 
would be given a prize reward or exclusive right as an incentive for the contribution.
26  The first true patent 
was issued in 1421 in Renaissance Italy, and the first true patent statute was enacted in 1474 by the Venetian 
Republic, seeking technological advancement and knowledge importation
27 by granting patents or importation 
license for the common good.
28  In order to encourage more people to invent ingenious devices, others were 
not allowed to make the same or similar devices without the patentee’s consent for ten years.
29  During 15
th 
and  16
th  centuries,  England  was  in  general  actively  granting  importation  franchises  and  monopolistic 
privileges.
30   However,  patent  practice  was  abused  in  reign  of  Elizabeth  I  (1558-1603)  and  James  I 
(1603-1625).  Not until in 1623 did Parliament pass the Statute of Monopolies, the first English patent statute 
governed English patent law for more than 200 years, to reflect a general skepticism about monopolies and to 
confirm the common law view that patents should not be tolerated if not serving the public good.
31  During the 
17
th and 18
th centuries, it become a common requirement to submit the specification, “a full description of the 
invention and its operation which would show the scope of the patent”
32, for the purpose of knowledge 
dissemination by the inventor to make it easier for others to build upon and enhance knowledge;
33 the law no 
longer concerned merely the introduction of inventive devices.
34  This specification requirement was included 
                                                 
26 DONALD CHISUM ET AL, PRINCIPALS OF PATENT LAW 7 (2004). 
27 Hestermeyer, supra note 5, at 22.  
28 Id .at 10, 11.  
29 Hestermeyer, supra note 5, at 22. 
30 Chisum, supra note 26, at 13. See also BRUCE BUGBEE, GENESIS OF AMERICAN PATENT AND COPYRIGHT LAW 34-35 (1967).   
31 Id.,at 15. See also Hestermeyer, supra note 5, at 23. See also CHRISTINE MACLEOD, INVENTING THE INDUSTRIAL REVOLUTION: THE 
ENGLISH PATENT SYSTEM 1, 17-19 (1988). 
32 Bugbee, supra note 30, at 41-42; See also GERARD DOORMAN, PATENTS FOR INVENTIONS IN THE NETHERLANDS DURING THE 16
TH, 
17
TH AND 18
TH CENTURIEs 22-23 (1942). 
33 See also H. DUTTON, THE PATENT SYSTEM AND INVENTIVE ACTIVITY DURING THE INDUSTRIAL REVOLUTION 1750-1853 (1984) 
34 Chisum, supra note 26, at 15   13 
and become a standard feature in the first US Patent Act, the Patent Act of 1970, based on the power that the 
US Constitution had granted to Congress to “promote the progress of science and useful arts, by securing for 
limited times to authors and inventors the exclusive right to their respective writings and discoveries.”
35  Under 
US Patent Act of 1790, it remained a discretionary affair to grant patents if it is deemed to be sufficiently 
useful and important, not that it has to be granted.  However, following Locke’s natural law theory arguing 
that every man has a natural right in the fruit of his labor, intellectual property is equivalent to other kind of 
property.  Patents at that time began to be granted as a right, notwithstanding that this natural law rationale is 
now almost universally rejected at the national level.
36  The US Supreme Court interpreted US Patent Act of 
1793 to be that an inventor has a right to be granted a patent.  In the 19
th century, many countries established its 
patent system, but, in the second half of 19
th century, it was confronted by an anti-patent free-trade movement.  
To its national development purpose, some countries decided not to adopt patent laws or establish exceptions 
for patentability.
37   
 
B. The Patentability of Pharmaceutical Products 
Modern US patent law grants patents on “any new and helpful process, machine, manufacture, or 
composition of matter, or any new and useful improvement thereof.”
38  Pharmaceutical products are chemical 
                                                 
35 U.S. CONST. art .I, ²8, cl 8. 
36 Hestermeyer, supra note 5, at 38. 
37 Id., at 26-27.  
38 35 U.S.C. ²101.   14 
compounds,  categorized  as  “composition  of  matter”  and  therefore  eligible  for  patent  protection.
39  
Pharmaceutical industry and chemical industry are generally acknowledged as industries that mostly relied on 
patent protection for the large amount of labor and funds invested in research and development.  New drugs, 
mainly profitable from patents in the monopoly market though the distribution of new drug manufactures, are 
not equally distributed as they are principally located in the United States.  
For fear of the negative effects on public health, however, many countries, such as France, Germany, 
Japan, Switzerland, Norway, and other developed countries, did not adopt patent protection for pharmaceutical 
products until the second half of the 20
th century. An alternative for countries in the face of public health crisis 
regarding to pharmaceutical patentability is to grant compulsory licenses whenever needed.   
 
2.  International Patent Law Prior to the TRIPS Agreement 
Due to the disharmony of national patent laws, many problems arose with the cross-border trade that 
sprang up in the 19
th century.  Prior to the TRIPS Agreement, only a small number of bilateral treaties served 
as remedies to the international patent law inconsistency.  In 1873, the international exhibition of inventions in 
Vienna marked a decisive victory for international patent harmonization.  This conference and subsequent 
conferences  resulted  in 1883  diplomatic  conference  in  Paris,  adopting  the  first  international  agreement 
regarding patent protection.  The Paris Convention for the Protection of Industrial Property (Paris Convention), 
                                                 
39 Hestermeyer, supra note 5, at 28.   15 
ratified by 129 states although some developing countries were reluctant to sign,
40 came into effect on July 7, 
1884 and has been revised a few times.
41  Nevertheless, the Paris Convention does not establish substantive 
standards for industrial property to which members must adhere.  Patent laws still diverged in member nations 
and as long as it abided by the premise of national treatment granted by the Paris Convention, a member state 
is free to enact statutes with fewer or more intellectual property protection.
42  Additionally, disputes between 
member nations are set to be settled by the International Court of Justice (ICJ) under Article 28 of the Paris 
Convention, but many member states do not recognize ICJ to have jurisdictions in their countries.  Even for 
member states that recognize its jurisdiction, ICJ rulings are not executed.  As a result,  infringement is unable 
to be remedied.
43  The World Intellectual Property Organization (WIPO) was created in 1967, later becoming 
a specialized agency of the United Nations, with a purpose “to encourage creative activity, [and] to promote 
the protection of intellectual property throughout the world,”
44 now administered the Paris Convention and 
other treaties.
45  “[D]espite WIPO’s efforts to promote international comity with respect to IPR protection, the 
level of harmonization across countries achieved by the mid-1980s remained limited.”
46  The problem of a 
                                                 
40 Id. at 39.  
41 PAUL GOLDSTEIN, INTERNATIONAL INTELLECTUAL PROPERTY LAW 299 (2001). 
42 MICHEL RYAN, KNOWLEDGE DIPLOMACY: GLOBAL COMPETITION AND THE POLITICS OF INTELLECTUAL PROPERTY 104 (1998). 
43 Evelyn Su, The Winners and the Losers: The Agreement on Trade-related Aspects of Intellectual Property Rights and Its Effects on 
Developing Countries, 23 Hous. J. Int'l L. 169, 179-180 (2000). 
44 Convention Establishing the World Intellectual Property Organization, signed at Stockholm on July 14, 1967, Preamble, second 
paragraph.. 
45 L. Danielle Tully, Prospects For Progress: The Trips Agreement And Developing Countries After The Doha Conference, 26 B.C. Int'l 
& Comp. L. Rev. 129, 132 (2003). 
46 Carlos A. Primo Braga, Trade-Related Intellectual Property Issues: The Uruguay Round Agreement and Its Economic Implications 3 
(1995) (paper presented at The Uruguay Round and the Developing Economies-A World Bank Conference)   16 
lack of coordination of every aspect of national patent laws remained
47 and thus resulted in a lack of 
intellectual property protection.  The weak protection of intellectual property, that is, allowing counterfeits, 
enabled many developing countries to have huge economic growth at that time.
48  However, since most 
patents are owned by companies from developed countries, these countries were seeking stronger protections 
over patents, claiming that the little or none patent protection in developing countries had formed barriers to 
international trade and made no contribution to, but profited from, knowledge development.
49  Though 
“piracy”  was  legal  within  these  weak  intellectual  property  protection  countries,  the  developed  country 
industries suffered from a significant loss.  On the other hand, from developing countries’ perspective, the 
stronger patent protection – some were made by their former colonial masters – was not consistent with the 
level of their economic development.
50  Moreover, free riding technology from abroad, would foster the 
technology development of these countries.  To date, this North-South debate continues.   
Therefore, with the failure of WIPO functions, the Untied States and European Communities imposed 
unilateral trade sanctions against individual developing countries, especially the United States’ use of section 
301 and special 301 in the areas of intellectual property laws of the US Trade Act of 1974 to advance US 
interest, where it was perceived as unjustifiable, unreasonable, discriminatory, or inconsistent with trade 
                                                 
47 Aspects that are lack of consistency include: minimum of the patent term, over-liberal compulsory licensing regulations, areas of 
patentability. See Hestermeyer, supra note 5, at 37. See also Frederick M Abbott, Protecting First World Assets in the Third World: 
Intellectual Property Negotiations in the GATT Multilateral Framework, 22 Vand J of Transnat’l L. 689, 703 (1989)   
48 N Kumer, Intellectual Property Rights, Technology and Economic Development: Experiences of Asian Countries, Commission on 
Intellectual Property Rights Study Paper 1b, 4 (2002) 
49 Lei, supra note 17, at 51. Hestermeyer, supra note 5, at 37. 
50 Sterckx, supra note 22, at 186.   17 
agreements.
51    
Meanwhile,  the  developed  world  does  not  give  up  seeking  a  multilateral  intellectual  property 
agreement to unify the intellectual property system.  In the linkage between intellectual property rights to 
international trade, the United States and other developed countries looked to include intellectual property 
rights in the General Agreement on Tariffs and Trade (GATT).
52  They had three major concerns: first, to 
enlarge their trade worldwide by prevailing international protection of intellectual property; second, to set up 
an effective mechanism to implement and settle disputes on intellectual property; third, to ensure that other 
countries follow developed country model, extending intellectual property rights to new innovation; thus 
earning profit therein.
53  
Since the GATT contains no direct provisions on intellectual property rights, and the most related 
provision is Article XX(d), later in the Uruguay Round, the intellectual property rights were finally included in 
trade  relations  mainly  under  the  pressure  from  the  United  States,
54 despite  the  strong  objection  from 
developing countries.  A new agreement, the Final Act of the Uruguay Round and the Marrakesh Agreement 
Establishing the World Trade Organization (hereinafter: the WTO Agreement), was signed by the end of the 
Uruguay Round in 1994. The Round transformed GATT into WTO.  
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3.  The TRIPS Agreement 
The  WTO Agreement consists of six main parts: the Multilateral Agreements on trade in goods 
including the GATT 1994, which includes the GATT 1974, and the Trade Related Investment Measures, trade 
in services (the General Agreement on Trade in Services (GATS)), intellectual property rights (the TRIPS 
Agreement), dispute settlement (Dispute Settlement Understanding (DSU)), and Reviews of governments’ 
trade policies (TPRM).  These agreements are all enforced by a stronger dispute settlement body, made up of 
all member governments.  If a trade dispute arises, the complainant can create a panel and the panel report can 
only be rejected when everyone agrees not to adopt it.  Appeals against a panel report can be filed with a 
standing Appellate Body, which is composed of seven members appointed by the Dispute Settlement Body to 
serve for four-year terms.
55  The WTO's mechanism for dispute settlement makes the trade function more 
secure than before, remedying the enforcement defects in the international intellectual property system.
56  
On the other hand, the negotiation process was full of hardships as the TRIPS Agreement only shifted 
the mode of argument between developed and developing countries.  Developed countries, such as the United 
States and Japan, sought a comprehensive agreement on intellectual property standards in order to protect the 
incentive for innovation while developing countries argued that the mandate only covered "trade-related" 
intellectual  property  rights,  referring  to  the  WIPO  for  the  comprehensive  intellectual  property  forum.
57  
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However,  confronted  with  the  developed  countries’  contention  of  the  “trade-related”  character  of  all 
intellectual property law, critics argue that similar effects can be claimed with many domestic regulations.
58  
The inclusion of intellectual property law into international trade law, the GATT/WTO system, is not strongly 
grounded and served the interest of developed countries.
59  Even though the developing countries finally gave 
up resisting the agreement, there were still many problems that needed to be addressed in the negotiations, 
such as the patentable subject-matters, non-discrimination, patent term, and burden of proof to compulsory 
licensing.
60   After  the  implementation  of  the  TRIPS  Agreement  had  been  implemented  for  years,  its 
consequences became clear.  Many developing countries’ dissatisfaction to the Agreement revived even more 
strongly, thereby contending the coercive character of the treaty.
61  
 
4. Pharmaceutical Patents under the TRIPS Agreement 
In the process of the TRIPS Agreement negotiations, developing countries demanded their exclusion 
from pharmaceutical patent protection since patent protection should not outweigh the public health needs.
62  
However, as a result of the discussion, Article 27(1) of the TRIPS Agreement implies that patent must be 
granted “for any inventions, whether products or processes, in all fields of technology…”, and that patent rights 
must be enjoyable “without discrimination as to …the field of technology.”  Therefore, since TRIPS is binding 
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on all Members, they are all obligated to grant pharmaceutical product patents.  
Nevertheless, the wording of the Agreement allows some degree of manipulation to accommodate of 
the public health concerns.
63  The TRIPS Agreement Article 1.1 provided that, “Members should give effect to 
the provisions of this Agreement.  Members may, but shall not be obliged to, implement in their law more 
extensive protection than is required by this Agreement, provided that such protection does not contravene the 
provisions of this Agreement.  Members shall be free to determine the appropriate method of implementing 
the provisions of this Agreement within their own legal system and practice.”
64 In short, it aims to impose a 
minimum standard to patent right protection on member nations.
65  
 
5. Flexibilities Under the TRIPS Agreement 
As Article 30 of the TRIPS Agreement states, “Members may provide limited exceptions to the 
exclusive rights conferred by a patent, provided that such exceptions do not unreasonably conflict with a 
normal exploitation of the patent and do not unreasonably prejudice the legitimate interests of the patent owner, 
taking account of the legitimate interests of third parties,” the wording of this article is very general and 
imposes no substantive limitation to the content of exceptions.  Thus, Members are entitled to decide the types 
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and scopes of limitations,
66 accommodating Members’ policy and implementation considerations.  In this 
study, the right to access to medicine would be used as an argument in the interpretation of the flexibilities.
67  
 
A. Parallel Imports 
The meaning of parallel imports is that the patented product placed in a country by the patent holder or 
with its consent is imported to another country without the permission of the right holder.  Profits can be 
earned from the price differences between these two countries; thus parallel imports would cause damage to 
patent  holder’s  capacity  to  differential  pricing  in  different  markets.    In  pharmaceutical  markets,  drug 
companies usually divide the markets by the territory of the nations, and adjust the prices of the same patented 
drug in different markets.  Different price setting may be due to people’s income standards, the amount of 
substitute, insurance coverage, manners of medical treatment or exchange rates.  The validity of parallel 
imports  depends  on  what  kind  of  exhaustion  principles  to  take  -  national  exhaustion  or  international 
exhaustion. That is, if national exhaustion is adopted, parallel imports are not allowed.  On the contrary, if 
international exhaustion is adopted, the patentee has no right to intervene in the parallel imports.  However, the 
TRIPS Agreement does not directly regulate parallel imports.  Article 6 of the TRIPS provides that, “For the 
purposes of dispute settlement under this Agreement, subject to the provisions of Articles 3 and 4 nothing in 
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this Agreement shall be used to address the issue of the exhaustion of intellectual property rights.”  It indicates 
that the adoption of a certain exhaustion principle is under the discretion of each Member.  No matter which 
exhaustion principle is taken, other Members cannot argue that it is a violation of the TRIPS Agreement.  
 
B. Compulsory Licensing 
Compulsory licenses are ones granted by the government after the completion of an administrative or 
judicial procedure, forcing a patentee to grant a license to third parties for the use of his patented product or 
process
68 to manufacture the generic drugs and thus creating competition.
69  Compulsory licenses can only be 
permitted to be used in the domestic market of the country that grants them, except for limited export.
70  As 
Article 31 of the TRIPS Agreement provided, “other use [than that permitted by Article 30 of the TRIPS 
Agreement] of the subject matter of a patent without the authorization of the right holder, including use by the 
government or third parties authorized by the government.”  It does not explicitly impose limitations for 
granting compulsory licenses so it becomes contentious as to under what kind of circumstances should the 
government  grant  compulsory  licenses.    Developing  countries  tended  to  confer  its  government  broad 
discretion to grant compulsory licenses, whereas developed countries assumed a restrictive approach in the 
interpretation of the Agreement.  The United States in the beginning even took a position of near-total ban on 
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granting  compulsory  licenses.
71    Nevertheless,  compulsory  licensing  is  an  important  method  in 
accommodating access to medicine with the patent right system.  
 
IV.  Efforts in Reconciliation Between Public Health Needs and Patent Protection: The Doha Declaration 
With the respect to the discussion of the difficulties experienced by developing countries in adopting the 
TRIPS flexibilities on pharmaceutical patents, although in the TRIPS flexibilities, the problem of access to 
medicine has been taken into account, the adoption of these flexibilities by Members who intend to make full 
use of these flexibilities still encounter many obstacles in practice, primarily because of the lack of legal 
security of the TRIPS flexibilities, lack of infrastructure in pharmaceutical industry, lack of corresponding 
legal and administrative supporting system, and pressure from industrialized countries with capacities to 
manufacture drugs.
72   
 
The Doha Declaration on the TRIPS Agreement and Public Health 
A group of eighty countries drove for a legally binding declaration to read the TRIPS Agreement as 
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allowing countries that seek to implement measures to promote access to affordable drugs do not have to fear 
retaliation by WTO or national governments.  In 2001, WTO Members adopted the so-called Doha 
Declaration on the TRIPS Agreement and Public Health
73 in the 4
th Session of the WTO Ministerial 
Conference, held at Doha, Quata.  Some ambiguities between government’s interest for public health and the 
interpretation of the flexibilities of the TRIPS Agreement were thus clarified in the Doha Declaration.  It 
affirms that “the TRIPS Agreement does not and should not prevent Members from taking measures to 
protect public health” and “the Agreement can and should be interpreted and implemented in a manner 
supportive of WTO Members’ right to protect public health and, in particular, to promote access to medicines 
for all” in the fourth paragraph.  Responding to the developing countries’ concerns of the difficulties they 
faced in taking measures to facilitate access to medicines while acknowledging the purpose of intellectual 
property protection is “for the development of new medicines”.
74  Here I just list some important parts of the 
Doha Declaration relevant to the flexibilities of the TRIP Agreement.  In its fifth paragraph, it states that:  
 
(b) Each Member has the right to grant compulsory licenses and the freedom to determine  
the grounds upon which such licenses are granted. 
(c) Each Member has the right to determine what constitute a national emergency or other 
circumstances if extreme urgency, it being understood that public health crises, including those  
relating to HIV/AIDS, tuberculosis, malaria and other epidemics, can represent a national  
emergency or other circumstances of extreme urgency… 
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Given the vague nature of the limitations for granting compulsory licenses in Article 31 of the TRIPS 
Agreement, and the pressures primarily from the U.S. under which developing countries encounter when 
planning to grant compulsory licenses, subparagraph (b) is very important to affirm a country’s freedom to 
embed its national public health interests in its intellectual property protection system in order to achieve a 
balance between patent holder’s rights and its obligations.  In addition, the value of subparagraph (c) is that it 
emphasizes every member state’s sovereign power to proclaim a (national) state of emergency,
75 and shift the 
burden of proof to the complaint party
76. 
Moreover, the sixth paragraph of the Doha Declaration addresses the problem that Members without 
sufficient pharmaceutical manufacturing capacities cannot make full use of compulsory licensing.  It provides 
that:  
 
We recognize that WTO Members with insufficient or no manufacturing capacities in the  
pharmaceutical sector could face difficulties in making effective use of compulsory licensing  
under the TRIPS Agreement. We instruct the Council for TRIPS to find an expeditious  
solution to this problem and to report to the General Council before the end of 2002. 
 
On August 30, 2003, the WTO General Council adopted an agreement on the implementation of 
paragraph six of the Doha Declaration.  This agreement recognized a temporary waiver allowing countries 
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producing patented drugs to export these products to eligible importing countries under certain conditions.
77  
However, these conditions appear to be burdensome for potential suppliers, and would discourage the use of 
such system.  Thus, the agreement can hardly meet its purpose to provide an expeditious solution.  In addition, 
only few countries, such as Norway, Canada, the EU, and India, have brought the waiver into their national 
laws.
78  This temporary waiver was then made permanent on December 6, 2006 as an amendment to the 
TRIPS Agreement.  Once this amendment was ratified by two-thirds of WTO member states, it becomes part 
of TRIPS and comes into effect in those Members, replacing the 2003 waiver.  The ratification deadline was 
originally set on December 1, 2007, but was extended to December 31, 2009 under a decision by the General 
Council on December 18, 2007.
79   
Generally, the Doha Declaration is applauded by the WTO Members and scholars for the efforts facing 
up to the conflicts between public health and the TRIPS Agreement and clarifying some ambiguities in the 
interpretation therein.  However, the Doha Declaration still does not provide a comprehensive resolution to the 
uncertain role of access to medicine in the WTO system, and the insecurity in the interpretation of the TRIP 
Agreement remains.
80   
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V.  Human Right Analysis of Access to Medicine 
1.  International Human Rights Relevant to Access to Medicine 
In determining the relationship between two regimes – human rights and intellectual property – under 
the framework of international human rights analysis, there are two different approaches:
81 the first regards 
these human rights and intellectual property fundamentally conflict with each other.  When strong intellectual 
property protection has undermined human rights, particularly in the area of economic, social, and cultural 
rights, they are incompatible.  In short, human rights law is superior to intellectual property law when they 
confronted with each other.  The second approach views both areas of laws as essentially compatible, provided 
that their scopes are appropriately defined.  It is possible to strike a balance between the two regimes.  In this 
study, I will engage in the second approach, allowing the adjustment of scopes of the rights because it is 
contributive to our understanding of both rights through the process of reconciliation.  
Under the framework of international human rights law, I will first walk through several sources of 
international law affirmed under the United Nations regime, holding that they have become customary 
international law; thus they are legally binding to all nations,
82 including the WTO Members.  Human rights 
relevant to access to medicine primarily involve the right to health, the right to life, and the right to enjoy the 
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benefits of scientific progress as we will discuss in the following paragraphs.  
 
A. The Right to Health 
Not until post-World War II did the concept of a human right to health began to develop.  The WHO, a 
specialized agency in the United Nations, directing and coordinating global health matters, was set up in 1948.  
The Constitution of the WHO is the first international legal acknowledgement explicitly covering the right to 
the “enjoyment of the highest attainable standard of health.”
83  To date, the access to medicine has been 
recognized by several sources of international law, including treaty law and international law.
84  There are two 
major international human rights Covenants regarding the protection of access to medicine – International 
Covenant on Civil and Political Rights
85 (the ICCPR), protecting access to life-saving medicine, and the 
International Covenant for Economic, Social and Cultural Rights (the ICESCR) protecting access to essential 
medicine.  
Access to medicine is contained in Article 12 of ICESCR as an integral part of the right to health, which 
reads:  
1. The States Parties to the present Covenant recognize the right of everyone to the  
enjoyment of the highest attainable standard of physical and mental health.  
2. The steps to be taken by the States Parties to the present Covenant to achieve the  
full realization of this right shall include those necessary for:  
(a) The provision for the reduction of the stillbirth-rate and of infant mortality  
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and for the healthy development of the child;  
(b) The improvement of all aspects of environmental and industrial hygiene;  
(c) The prevention, treatment and control of epidemic, endemic, occupational and  
other diseases;  
(d) The creation of conditions which would assure to all medical service and medical  
attention in the event of sickness. 
 
In Article 2(1) of the ICESCR, States Parties are under obligations to live up to the goals set above:  
Each State Party to the present Covenant undertakes to take steps, individually and through international 
assistance and co-operation, especially economic and technical, to the maximum of its available resources, with a 
view to achieving progressively the full realization of the rights recognized in the present Covenant by all 
appropriate means, including particularly the adoption of legislative measures. 
Therefore, the standard of the right to health includes “a wide range of socio-economic factors that 
promote conditions in which people can lead a healthy life, and extends to the underlying determinants of 
health, such as food and nutrition, housing, access to safe and potable water and adequate sanitation, safe and 
healthy working conditions, and a healthy environment,” not limiting to the right to health care.
86  In pursuing 
other socio-economic rights, the right to health care, including the medicine, is most fundamental in the 
“dignity and worth of the human person” in which human rights are based on.  At the present time, medication 
is playing a vital and indispensable role in preventing, controlling, and treating diseases.  Thus, the right to 
medicine is embraced in the right to health in order to reach individual’s “highest attainable standard of 
physical and mental health.”  Several countries also have had chance to clarify through adjudication that the 
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accessibility of medicine is part of the right to health.
87  In the CESCR General Comment No 14,
88 it has been 
stated that the right to health contains four interrelated dimensions: the availability of sufficient quantity of 
medicines, the accessibility to treatment of all groups of populations without discrimination, the acceptability 
of treatment being ethically and culturally appropriate, and the scientifically appropriate quality of medicine.  
These four elements serve as indicators of State Parties’ success to achieve the right to health.  Among these 
four dimensions, the economic accessibility of medicine is essential and States are obligated to provide such 
accessibility.  
 
B. The Right to Life 
Many  epidemics  have  high  mortality  rates.    Human  health  is  acutely  threatened  if  appropriate 
pharmaceuticals are not provided in time.  The realization of the right to life is the premise of other human 
rights.  In Article 3 of the Universal Declaration of Human Rights, it provides that, “Everyone has right to life, 
liberty and security of person.”
89  And in Article 6.1 of the ICCPR, “Every human being has the inherent right 
to life.  This right shall be protected by law.  No one shall be arbitrarily deprived of his life” also contains 
protection of the right to life.  
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C. The Right to Enjoy the Benefits of Scientific Progress 
According to Article 15(1)(b) of the ICESCR: “The States Parties to the present Covenant recognize the right 
of everyone: (b) To enjoy the benefits of scientific progress and its applications.” 
Scientific progress and its applications include “existing tools, interventions and knowledge as well as 
those that do not yet exist.”
90  It is no doubt that new drugs are under the catalog of scientific progress; thus 
access to medicine is protected as significant human right.  States Parties are under obligation of Article 15(2) 
to take steps to realize this human right.  However, in Article 15(1)(c), individuals have the right to “benefit 
from the protection of the moral and material interests resulting from any scientific, literary or artistic 
production of which he is the author.”  Hence, there is a debate over whether intellectual property tights are 
included in Article 15(1)(c).
91  In any event, even if accepting the argument that intellectual property rights is 
encompassed, since these two rights are co-exist in Article 15, a balance should be stricken, and there is no 
implication that intellectual property rights should outweigh the right to health.  
 
2. Solving the Conflict Between Intellectual Property Rights and Human Right of Access to Medicine 
In this section, I am going to argue in favor of the right to access to medicine when public health 
emergencies emerge in a country and the drug patent holder’s right should yield.  
First, the Committee on Economic, Social and Cultural Rights published a statement on human rights 
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and intellectual property rights in 2000, making the distinction between human rights and intellectual property 
rights and clarifying that treaties, including the TRIPS Agreement, should be implemented consistently with 
international human rights law.  It has been noted by the Committee that “human rights are fundamental, 
inalienable and universal entitlements belonging to individuals,” compared to “intellectual property rights 
derived from intellectual property systems are instrumental, in that they are a means by which States seek to 
provide  incentives  for  inventiveness  and  creativity  from  which  society  benefits”
92   From  the  historical 
perspective of patent development discussed in Part III, we have become aware that patent granting is not an 
absolute right, and its grant is under discretion of the national authorities served as a mechanism for the 
encouragement of scientific progress.  The ultimate purpose of scientific advancement is for the welfare of 
human being.  On the contrary, access to medicine is in the core component of the human right to health.  It 
has been universally acknowledged for states to be obligated to fully realize this human right.   
Therefore, in my opinion, patent protection for pharmaceutical products as an instrumental tool should 
ultimately serve the fundamental goal of human rights protection, the social good, through efficient application 
of the flexibilities provided by existing WTO regime in the face of national public health emergency.  
Otherwise, the over emphasis on patent protection, in the negligent of its purpose to facilitate human health, 
overlooks the essential value of the grant of patent protection.  Merely the incentive function of patents cannot 
justify the opposition measures taken by some pharmaceutical companies in the  industrialized countries 
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against compulsory licensing in developing countries.  “An interference with access to today’s medicine with 
the protection of access to tomorrow’s medicine”
93 cannot serve as an equivalent argument against people in 
desperate  need  for  medicine  in  developing  countries.    Mental  and  physical  health  is  the  basis  of  the 
development of human dignity; it is the obligation of the government not to intrude on individual health and 
also actively to respect, to protect and fulfill the integrity of individual’s right to health.    
Secondly, given the dual character of pharmaceutical products
94- ordinarily as commodities advancing 
people’s lives but sometimes working as the most basic, even life-saving, dimension improving the quality of 
lives, these products cannot be treated as merely ordinary commodities.  Unlike those ordinary commodities 
which stress the value of free market, medicine’s public interest peculiarity and its direct influence to human 
health, often shown in the national public health crisis, has bestowed itself to more intervention of national 
regulatory power to ensure access to medicine.  When private market has proven to fail in its major function of 
efficiency and cannot properly distribute essential resources to the people in need, it is the time for public 
mechanism to intervene.  Weaker patent protection in the face of national emergency or other circumstances of 
extreme emergency is thus justified.  However, letting the government be the only institution to shoulder all 
the responsibilities of improving access to medicines is not always efficient.  We will discuss other alternatives 
in the next section.  
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3. Possible Solutions to Improve Access to Medicine 
A.  Importing Human Rights Considerations into the WTO Law and Beyond 
The conflict between the TRIPS Agreement and access to medicine is substantially a conflict between 
the world trade regime and the human rights regime.  On account of the WTO regime’s strong and effective 
enforcement mechanism, it is on a higher level in a factual hierarchy; whereas the human rights regime has a 
relatively  weaker  enforcement  system  despite  its  higher  normative  appeal  than  the  WTO  regime.  
Consequently, in practice, states are more likely to comply with the dispute solutions within the WTO rather 
than abide by human rights requirements.  Therefore, it is important to accommodate human rights law with 
the WTO system, and the only solution to secure the access to medicine whenever conflict happens is by 
conferring human rights law a stronger status within the WTO system.
95  
In the efforts to import human rights considerations into WTO law, it can be first done through taking 
the right to access to medicine, which is under the ICESCR, ICCPR and general international law, into 
account in the interpretation of the existing flexibilities of the TRIPS Agreement. Moreover, the Appellate 
Body can import human rights to medicine in public health threats as a broad, modern definition of “security” 
in accordance with Article 73 of the TRIPS Agreement,
96  allowing Members to prioritize the necessary 
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treatment of pandemics for the protection of its essential security interests. 
Secondly, through the amendment to the WTO Agreements to accommodate human rights, a separate 
WTO human rights treaty can be enacted or referred to the ICESCR or the ICCPR.
97 
The third option is through either cooperative arrangement or informal cooperation between the WTO 
and other human rights related organizations, to encourage cross influence and mutual understanding.
98 
However, the challenges are that, beyond the WTO system, many developed countries, in particular the 
United States, now seek their negotiation field to free trade agreements and bilateral investment treaties to 
include intellectual property rights that may have the  effect of limiting TRIPS flexibilities or imposing 
additional obligations as these agreements are interpreted independently of the TRIPS Agreement.  This 
potential conflict may be solved by reading the term “intellectual property” in these agreements or treaties as 
reference to the intellectual property rights defined in the TRIPS Agreement.
99 
 
B.  Technology Transfer to Developing Countries 
Once the manufacturing capacity of pharmaceuticals has been established, it can benefit the state 
economy as well as enable the government to make full use of its compulsory licensing system to deal with 
public health crises.  Therefore, in order to solve the problem of access to medicine in developing countries, 
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building up the local manufacturing capacity of pharmaceuticals is a better solution in the long run.  However, 
pharmaceutical  industry  requires  high  technology  intensity;  hence,  short  of  technology  transfer,  the 
manufacturing capacity is difficult to build by developing country itself.  In accordance with Article 7 of the 
TRIPS Agreement, which provides that “the protection and enforcement of intellectual property rights should 
contribute to the promotion of technological innovation and to the transfer and dissemination of technology, to 
the mutual advantage of producers and users of technological knowledge and in a manner conducive to social 
and economic welfare, and to a balance of rights and obligations,” and Article 66(2), which provides that 
“developed country Members shall provide incentives to enterprises and institutions in their territories for the 
purpose of promoting and encouraging technology transfer to least-developed country Members in order to 
enable them to create a sound and viable technological base.”  Technology transfer is within the objectives of 
the intellectual property rights and developed countries are obligated to live up to the goal.   
However, the least-developed countries have complained that the commitment to technology transfer is 
not carried out by developed countries
100  What’s worse, the importation of highly competitive intellectual 
property-intensive products has the negative effect of forcing local manufacturers out of the market.
101  Even 
though the Doha Declaration has reaffirmed the developed countries’ obligation under Article 66 (2) of a 
Working Group on Trade and Transfer of Technology to be set up, the goal of technology transfer to less 
industrialized  countries  has  not  been  accomplished.    In  the  international  trading  regime,  “some  highly 
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vulnerable members of the WTO [has been disempowered] from the benefits of a liberal trading order by 
loading them with undue burdens for commitments made by participating in the regime.  The most damning 
indictment against the international trading regime is that it formally entrenches uneven consequences for 
developing  and  developed  countries.”
102   The  benefits  and  burdens  of  international  trade  should  be 
proportionately allocated to developing countries.  Thus, given that the obligation regulation of technology 
transfer in Article 66(2) of the TRIPS Agreement is relatively rough compared to other denser regulation 
protecting intellectual property right, the WTO should reexamine its regulation as well as implementation on 
the transfer of pharmaceutical technology.  
 
C.  WIPO Should Be Responsible for Assisting Developing Countries with Bringing the Flexibilities 
into Legislation 
The legislation of many developing countries has not yet included the mechanism of flexibilities of the 
TRIPS Agreement, and this is partly due to their lack of ability to enact related laws that are helpful in 
resolving the problem of access to medicine.  Since the duties of the WIPO involve assisting Members to 
establish intellectual property law, it should be responsible for providing assistance to developing countries, 
enacting laws that are in consistent to the flexibilities of the TRIPS Agreement, the Doha Declaration, and their 
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national interest.
103  
 
D.  A Critical Role of Non-state Actors 
Since the dual character of medicine as a commodity on one hand and as a product vital to human 
health on the other, and the fact that the privately owned pharmaceutical industry has long dominated the 
creation and manufacture of drugs, despite public funding to research, a tension has arisen between the state 
authority and private entities.  Yet the dual character of medicine makes it so that theses manufacturers cannot 
shirk their responsibility when their product appear vital to human health.  Because of their enormous impact 
on the lives of individuals, the pharmaceutical industry should be held accountable.
104 
In addition to relying on the government to carry out the task of providing access to medicine, non-state 
actors,  such  as  non-governmental  organizations,  communities,  pharmaceutical  companies  and  health 
professionals sometimes are more efficient and capable than governments in taking responsibilities to respect, 
protect and fulfill the right to health.
105  Moreover, civil society groups can put pressure to the governments to 
realize their obligations under human rights law.  They are also capable of bringing in potential human rights 
concerns, working at the grass-root level and suggesting possible remedies.
106  With an increasing role of these 
non-state actors, human rights are better served. 
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E.  Incentives of Pharmaceutical Manufacturers 
The objection of the pharmaceutical industry to the grant of compulsory licensing, for instance, is 
because strong patent protection, allowing them to set high prices on the market without fear of being undercut 
by competitors, provides an indispensable incentive for research and development for invention.  However, in 
my opinion, strong patent protection only provides a manner of incentive for invention, for its function to 
guarantee monopoly pricing as a return for pharmaceutical companies’ great investment on research and 
development.    Thus,  this  monetary  incentive  for  innovation  can  also  be  achieved  by  other  means  of 
subsidizing the potential patent holder, that is, to ensure enough money would be made.  Though it cannot be 
denied that strong patent protection is the utmost way for pharmaceutical industry to make profits, it should be 
recognized that due to this industry’s product that has vital impact on human health and its social responsibility 
to human rights, the companies should make a concession to less profit when the loss of profit serves for 
people desperate in need provided that the flexibilities are soundly implemented.  This potential profit loss 
should be considered expected and thus included in the company’s policy making.  After all, the ultimate 
purpose of the invention of pharmaceuticals is for technology advancement and for further human health. 
Therefore, if other fund resources are ensured, they can also serve as incentives for the pharmaceutical’s 
invention to assure wide access to pharmaceuticals when they are developed.  Possible solutions to provide 
incentive are by investing government fund or grant in desired research or by  some other institution’s   40 
commitment to fully or partially finance purchase before drugs have been developed.
107  
 
F.  Creating an Environment Favorable for Differential Pricing 
Pharmaceutical companies’ policy to engage in differential pricing is able to serve the need of people in 
developing countries for lower priced drugs in response to their small buying power while the pharmaceutical 
companies make profit.  Therefore it contributes to resolving the problem of access to medicine in developing 
countries.  However, the major difficulties in implementation of differential pricing are, first, fail to distinguish 
markets charging different prices, and the drugs in low prices are circulated to other markets, thereby reducing 
pharmaceutical companies’ profit in other markets; second, people in developed countries are reluctant to pay 
for  higher  prices,  stressing  pharmaceutical  companies  to  drop  drug  prices  according  to  their  price  in 
developing  countries.
108   In  removing  these  obstacles  to  create  an  environment  favorable  for  adopting 
differential pricing, developing countries may adopt national exhaustion to stop parallel imports that serves 
both  its  interests  and that  of  drug  companies.   Although  under  the  TRIPS  Agreement  and  the  Doha 
Declaration, states are free to decide which exhaustion principle to take.  Furthermore, in view of duly 
contribution of resources worldwide, it may be appropriate for developed countries to pay higher price for 
drugs than so as to compensate for the cost of research an development, and to encourage differential pricing 
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in developing countries.
109   
 
VI.  Conclusion 
     Many epidemics are curable or manageable, but the treatments are sometimes unaffordable to people in the 
developing world.  People die from having no access to medicines, which deteriorates the development of 
these less-industrialized countries.  After the TRIPS Agreement was brought into force, developing countries 
in most circumstances can no longer depend on generic drugs; thus, access to medicine become even more 
limited.  To solve the controversy in interpreting the TRIPS Agreement and the generated public health crises, 
the Doha Declaration was adopted.  In the Doha Declaration, the flexibilities of the TRIPS Agreement are 
recognized as effective and vital manners to promote access to medicines.  That is, in certain emergency 
circumstances, public health needs can outweigh the right of pharmaceutical patent holders.  The same 
conclusion can be drawn from the examination of international human rights law.   
In order to accommodate the public health needs, in particular the access to medicine, this paper 
suggests a flexible intellectual property regime – taking human rights concerns in interpreting the TRIPS 
Agreement or adopting amendments relevant to accessibility of medicine to other WTO Agreements.  It can 
also  be  achieved  by  the  WTO's  cooperation  with  other  human  rights  related  organizations  or  through 
importation of the definition of "intellectual property" in the TRIPS Agreement to other free trade agreements 
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and bilateral investment treaties.     
     Furthermore, the goal of transferring technology to developing countries set in the Article 7 and 66 (2) of 
the TRIPS Agreement should be put into practice.  WIPO should be responsible for providing assistance to 
developing countries to adopt the flexibilities into their legislation based on their specific needs. 
     In addition, non-state actors, including pharmaceutical companies, also play an increasingly critical role in 
promoting the right to health.  The incentives for innovation cannot only be provided by patent while the 
industry recognizes its responsibility in public health crises and makes concession to its maximum profit made 
through monopoly pricing.  Other public or private fund resources can all  be served for incentives for 
invention.    Moreover,  the  willingness  of  pharmaceutical  companies  to  engage  in  differential  pricing 
contributes to the solution for the access to medicine.  Thus, it is important for developing countries to create 
an environment beneficial for differential pricing.   
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